

# Clinical trials of losartan+ACE inhibitor

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>losartan+ACE inhibitor vs ACE inhibitor only</b>			
<a href="#">Hamroff et al. , 1999</a> n=16/17 follow-up: 6 mo	Losartan, 50 mg daily (plus ACE inhibitor) versus Placebo (plus ACE inhibitor)	patients with severe congestive heart failure (NYHA III-IV) despite treatment with maximally recommended or tolerated doses of ACE inhibitors	Parallel groups double blind

More details and results :

- angiotensin-receptor blockers for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q65>
- angiotensin-receptor blockers for heart failure in patients already receiving ACE inhibitor at <http://www.trialresultscenter.org/go-Q68>

## References

### Hamroff et al., 1999:

Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. *Circulation* 1999 Mar 2;99:990-2 [[10051289](#)]

Entry terms: losartan, Losartan, Cozaar, MK-954, MK 954, MK954, DuP-753, DuP 753, DuP753, Losartan Potassium, Losartan Monopotasium Salt,